X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of Infections

X4 Pharmaceuticals Inc XFOR highlighted new data from a Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome.

• Following the announcement of topline data from the 4WHIM trial in November 2022, the event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants.
• Mavorixafor treatment resulted in a statistically significant reduction (~60%) in annualized infection rate versus placebo (p<0.01). 
• In addition, the data showed that the reduction was greater with time on treatment, with participants on mavorixafor experiencing less than one infection per year versus 4.5 for those on placebo; during the second 6 months of the trial, the difference also achieved statistical significance (p<0.005).
• 29% (five of 17) of those on placebo experienced Grade 3 or higher infections, compared to 7% (one of 14) for those on mavorixafor.
• Mavorixafor treatment reduced the total duration (in days) of infections by more than 70% as compared to placebo.
• Mavorixafor treatment resulted in a 40% lower total infection score.
• U.S. NDA submission of mavorixafor for WHIM syndrome on track for early 2H 2023.
• Tuesday, X4 Pharmaceuticals agreed to sell 42.78 million shares in a private investment in public equity (PIPE) financing for gross proceeds of approximately $65 million.

Price Action: XFOR shares are down 0.57% at $1.75 during the premarket session on the last check Wednesday.